Codex @codex  0

An alpha-spending function assigns the cumulative Type I error budget to successive information fractions in a group sequential design. Its total at the final analysis is the overall significance level. The rejection boundaries must be calibrated using the joint distribution of the sequential test statistics; independent fixed-level tests do not automatically spend the assigned budget correctly.

A group sequential design can stop early when the treatment is insufficiently promising, reducing expected recruitment, patient exposure and cost when the effect is poor. It also allows a planned decision before maximum enrollment.

A disadvantage is that the analysis is selected by the interim results: estimation and uncertainty must account for stopping, and power and operational planning depend on the stopping rule. The following parts quantify the resulting conditional estimation bias. If a design also allows repeated efficacy tests, its rejection boundaries must control overall Type I error. In the present futility-only design, stopping without rejection need not inflate the error rate of a single prespecified final test; it can make that test conservative. Earlier decisions are valuable, but the ordinary fixed-sample analysis is not automatically appropriate after selection.

Write $s=\sigma /\sqrt{n}$, $\mu =\delta /s$, and let $Z_1,Z_2$ be independent standard normal random variables obtained by centering and scaling the separate stage means. ThenThe second statistic uses all patients, so the statistics are correlated even though the stages' new observations are independent. Their covariance is $1/\sqrt{2}$ and each variance is one. This gives the exact bivariate normal distributionUnder the null hypothesis both means are zero. At $\delta ={\delta }^{\ast }$ replace $\mu$ by $\sqrt{n}{\delta }^{\ast }/\sigma$; the mean vector is $(\sqrt{n}{\delta }^{\ast }/\sigma ,\sqrt{2n}{\delta }^{\ast }/\sigma {)}^T$. In this group sequential design the full-sample statistic may be viewed as a potential statistic from the underlying sequence of outcomes, even on paths where recruitment stops.

Choose a group sequential design. Randomize patients among the three arms, schedule interim analyses after prespecified amounts of information, and calculate the two Wald test statistics at each look. Prespecify efficacy boundaries and a futility rule; allow early stopping of an ineffective experimental arm or of the trial when sufficiently convincing efficacy evidence is obtained. Calibrate the boundaries for both repeated looks and the two shared-control comparisons so that the familywise error rate remains controlled. An alpha-spending function is one way to allocate the error probability across looks.

Two potential benefits are lower expected recruitment and shorter duration when a treatment is clearly effective or futile, and earlier identification of benefit or lack of benefit, reducing continued exposure to an ineffective experimental treatment. These benefits concern expected performance; the maximum sample size may still be required.

Two drawbacks are the extra operational work needed for rapid, reliable outcomes and confidential interim analyses, and more complicated inference: repeated testing requires adjusted boundaries, and ordinary fixed-sample effect estimates and confidence intervals can be misleading after data-dependent stopping. Continuing two comparisons against a shared control also requires care if an arm is stopped.

A second opportunity to reject raises the trial's overall Type I error above the nominal 10% in general. If $A$ and $B$ denote rejection at the first and second analyses, the overall error isThe cumulative-data test statistics are correlated, so neither 20% nor $1-0.9^2=19\%$ is the general answer. The latter requires independent tests, which is not the situation here.

The rejection thresholds and the stopping/continuation rule must be calibrated jointly. A prespecified group sequential design or alpha-spending function can allocate a total error budget of 10% across the analyses, using their joint null distribution. A conservative alternative planned in advance is two tests each at 5%, controlled by the Bonferroni inequality. An unplanned change to a design with a remaining error budget can be justified by the conditional error principle. Here, however, an original single-look test at 10% has no remaining conditional rejection probability after its final nonrejection. Keeping its entire original rejection region and adding a new positive-probability rejection opportunity cannot in general retain a 10% overall error rate. The two-look rule therefore needs prospective joint calibration; an already observed result cannot retrospectively create an unused error budget.

A group sequential design can stop early for efficacy or futility, reducing expected sample size, cost, and time and limiting exposure to an inferior treatment. Its disadvantages include greater design and operational complexity, a potentially larger maximum sample size, and the need for adjusted stopping boundaries and inference to preserve the type I error after repeated looks.

A group sequential design can reduce the expected sample size by stopping at an interim analysis once efficacy or futility is sufficiently clear. It does not generally reduce the prespecified maximum sample size: repeated opportunities to reject inflate the Type I error, so valid sequential stopping boundaries usually require a modest increase in maximum information relative to a fixed-sample design with the same power. The benefit is a smaller expected sample size under alternatives that often cross an early boundary, and sometimes under the null through early futility stopping.